top of page

AVISI      FOXC1 ImmunoHistoChemistry

Breast Cancer Test 

TM

0

For in vitro diagnostic use *

A semi-quantitative immunohistochemical assay to determine FOXC1 protein over expression in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue routinely processed for histological evaluation using light microscopy. 

 

The AVISI0™ FOXC1 (B2E3) murine monoclonal antibody is intended to assist in the diagnosis of invasive Basal-Like Breast Cancer (BLBC).   The clinical interpretation of AVISI0™ FOXC1 staining or its absence should be evaluated using proper controls, cellular morphology, the patient's clinical history, and other diagnostic tests by qualified pathologists.

​

* Not available in the United States and certain countries throughout the world.

AVISI0™ FOXC1 ImmunoHistoChemistry

Breast Cancer Test

For in vitro diagnostics *

* Not available in the United States and certain countries throughout the world.

Genomic Research at the turn of the century established the existence of breast cancer molecular sub-types. 

 20-years later, the Basal-Like subtype still eludes detection.  

Seamless Integration into Routine Laboratory Workflow

  • Utilizes existing standard equipment in histology lab.

  • Standard IHC protocols on FFPE samples.

  • Optimized for easy conversion and implementation onto automated IHC staining systems.

 

Easy to Interpret Microscopic Evaluation

  • Nuclear Stain vs Membrane Stain

  • Light Microscopy - Does not require added expense and complexities of fluorescent microscopy.

  • Industry accepted Allred scoring procedure slightly modified.

  • FOXC1 not expressed in the nucleus of normal breast tissue.

Modified Allred Score

bottom of page